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The untranslated leader sequences of rhesus macaque simian immunodeficiency virus mRNAs form a stable
secondary structure, TAR. This structure can be modified by RNA splicing. In this study, the role of TAR
splicing in virus replication was investigated. The proportion of viral RNAs containing a spliced TAR structure
is high early after infection and decreases at later times. Moreover, proviruses containing mutations which
prevent TAR splicing are significantly delayed in replication. These mutant viruses require approximately 20
days to achieve half-maximal virus production, in contrast to wild-type viruses, which require approximately
8 days. We attribute this delay to the inefficient translation of unspliced-TAR-containing mRNAs. The
molecular basis for this translational effect was examined in in vitro assays. We found that spliced-TAR-
containing mRNAs were translated up to 8.5 times more efficiently than were similar mRNAs containing an
unspliced TAR leader. Furthermore, these spliced-TAR-containing mRNAs were more efficiently associated
with ribosomes. We postulate that the level of TAR splicing provides a balance for the optimal expression of
both viral proteins and genomic RNA and therefore ultimately controls the production of infectious virions.
The life cycles of the primate immunodeficiency viruses,
including human immunodeficiency virus types 1 and 2
(HIV-1 and HIV-2) and simian immunodeficiency viruses
(SIVs), are regulated, in part, by a number of cis- and
trans-acting viral factors which affect various aspects of
either viral infectivity or expression (reviewed in references
7, 8, 10, and 15). Included among these factors is the Tat
protein, which activates expression from viral long terminal
repeats (LTRs) containing a trans-acting responder se-
quence element, TAR (2, 40). TAR is located downstream
from the start site of transcription and is therefore present at
the 5' ends of all viral mRNAs (24, 34). HIV-1 TAR RNA
adopts a secondary structure that is required for its activity
(4, 11, 24, 35, 37). Nucleotides from positions +1 through
+59 form a stem-loop structure that contains a three-nucle-
otide-long single-stranded bulge preceding the terminal loop
(24). The Tat protein binds to this structure on nascent viral
RNAs (5). When it is bound to TAR, Tat presumably
interacts with upstream promoter elements and thereby
stimulates transcription (3).
The HIV-1 TAR structure also interferes with translation.
Heterologous mRNAs that contain an HIV-1 untranslated
leader sequence, including the TAR structure, are translated
less efficiently than are similar mRNAs lacking a viral leader
(29, 38). There are at least two mechanisms that can explain
the translational inhibition caused by the HIV-1 leader.
First, the TAR structure may inhibit the binding of a 40S
ribosome subunit-initiation factor complex to the mRNA cap
structure, m7GpppN (19, 20, 30; for reviews, see references
22 and 31). Second, HIV-1 TAR has been reported to
activate the double-stranded RNA-dependent kinase dsl
(also called p68 or DAI) (9, 38, 39). The activated form of
this kinase phosphorylates the alpha subunit of the transla-
tional initiation factor eIF-2 (reviewed in references 23 and
* Corresponding author.
32). When phosphorylated, eIF-2 is not recycled and trans-
lation is inhibited.
Like HIV-1, rhesus macaque SIV (SIVmac) TAR RNA is
predicted to adopt a stable secondary structure (nucleotides
+1 through +124) (1). However, the SIVmac TAR structure
is predicted to contain three stem-loops, the first two of
which are similar in both sequence and structure to the
HIV-1 TAR stem-loop. In fact, the HIV-1 and SIVmac TAR
elements are partially functionally interchangeable (1, 42). In
HeLa and Jurkat cells, SIVmac and HIV-1 Tat are equally
effective in activating expression from the SIVmac LTR,
whereas SIVmac Tat is significantly less effective than
HIV-1 Tat in activating expression from the HIV-1 LTR (1,
42). Therefore, although the SIVmac and HIV-1 TAR struc-
tures have diverged, they have maintained at least some
functional homology.
The 5' untranslated ends of SIVmac mRNAs can be
modified by the splicing of an intron (nucleotides +60
through +203) which overlaps the SIVmac TAR structure (6,
43). The spliced form of SIVmac TAR is predicted to be
simpler and less stable (AG = -28.8 kcal [-120.5 kJ] mol-1)
than the unspliced form (AG = -53.1 kcal [-222.2 kJ]
mol-1). Instead of three stem-loops, spliced TAR is pre-
dicted to contain only a single stem-loop. Here we present
nuclease digestion data supporting these predictions. Fur-
thermore, we present three lines of evidence indicating that
TAR splicing is pivotal in the SIVmac life cycle. First, the
proportion of spliced-TAR-containing SIVmac mRNAs
changes throughout the course of infection. At early times
after infection (91 h), approximately 60% of SIVmac mRNAs
contain a spliced TAR element, whereas at later times (15
days), approximately 10% of SIVmac mRNAs contain a
spliced TAR element. Second, proviruses containing muta-
tions which prevent TAR splicing display significantly de-
layed growth early after transfection (1 to 15 days) but
achieve near-wild-type levels at later times (15 to 30 days).
Third, mRNAs containing a spliced TAR leader sequence
are translated up to 8.5-fold more efficiently in rabbit retic-
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ulocyte lysates than are mRNAs containing an unspliced
TAR leader. This effect on translation is reflected by the
enhanced ability of spliced-TAR-containing mRNAs to as-
sociate with ribosomes.
MATERIALS AND METHODS
Virus and plasmid constructions. The polymerase chain
reaction (25) and conventional cloning techniques (36) were
used to construct an SIVmac provirus clone (derived from
isolate BK28 [18]) that lacks substantial flanking cellular
sequences. The resultant clone, pBK.1, is a full-length
provirus without flanking 5' cellular sequences but with
approximately 100 bp of flanking 3' cellular sequences.
Mutagenesis of pBK.1 was performed by using the thio-
nucleotide incorporation method (Amersham) as described
previously (27). pBKSA1 is a full-length provirus containing
a mutation at the TAR intron 3' splice site; pBKSD12A1
contains mutations at both the TAR intron 5' and 3' splice
sites. All mutations were confirmed by DNA sequencing.
Plasmids used as templates for the in vitro transcription of
the various forms of either TAR or TARCAT RNAs were
constructed by using both polymerase chain reaction and
conventional cloning techniques. Plasmids pT7TARCAT
pT7ATARCAT, and pT7AHCAT express chloramphenicol
acetyltransferase (CAT) mRNAs with TAR leader se-
quences. All of these plasmids contain the T7 promoter
positioned such that transcription begins one nucleotide (a
G) before the beginning of TAR. The leader of TARCAT
mRNAs includes SIVmac nucleotides +1 through +466. The
leader of ATARCAT is the spliced form of the sequence
found in TARCAT mRNAs and therefore lacks SIVmac
nucleotides +60 through +204. The leader of AHCAT
mRNA includes SIVmac nucleotides +1 through +218.
Plasmid pT7F-CAT contains a CAT gene fragment inserted
into pSP73 (Promega).
Plasmids pT7KGTAR and pT7KGATAR contain the T7
promoter placed upstream of TAR such that transcription
begins either 45 (pT7KGTAR) or 62 (pT7KGATAR) nucleo-
tides before TAR. pT7KGTAR includes SIVmac nucleotides
+1 through +466. pT7KGATAR contains a spliced TAR
element and therefore lacks SIVmac nucleotides +60
through +204. The extra nucleotides present before the
beginning of the TAR elements in the RNAs expressed by
pT7KGTAR include 5'-GGGAGACCGGAAUUCGAGCUC
GGUACCCAUUUAGGUGACACUAUA-3'. Those before
the beginning of TAR in the RNAs expressed by pT7KGA
TAR include 5'-GGGAGACCGGAAUUCGAGCUCGGU
ACCCGGGGAUCCUCUAGAGUCAUUUAGGUGACAC
UAUA-3'. These extra sequences were included 5' to TAR
because we found that TAR RNAs that begin at the same
nucleotide as the normal SIVmac mRNA could not be
efficiently labeled with polynucleotide kinase. These extra
nucleotides do not interfere with the TAR secondary struc-
tures (data not shown).
Virus analysis. Virus titers of SIVmac (BK28) were deter-
mined by duplicate end-point dilution and reverse tran-
scriptase assays (12) on CEMx174 cells (16). To analyze the
temporal pattern of TAR splicing, CEMx174 cells were
infected at a multiplicity of 0.01 infectious virion per cell.
Total RNAs were prepared at 93 h and 15 days after
infection.
CEMx174 cells (107) were transfected by using DEAE-
dextran according to published procedures (33). Cells were
transfected with 1 ,ug of either pBK.1, pBKSA1, or
pBKSD12A1.
Western immunoblot analysis. Cell lysates (equivalent to
106 infected cells) were separated on sodium dodecyl sulfate
(SDS)-10% polyacrylamide gels and electrophoretically
transfered to polyvinylidene difluoride membranes (Immo-
bilon P; Millipore Corp.). The membranes were preincu-
bated (30 min, room temperature) in blocking buffer (0.1%
Tween 20, 0.9% NaCl, 5% nonfat dry milk, 10 mM Tris [pH
7.4]) and then in the same solution containing a 1:500 dilution
of serum from an SIVmac-infected rhesus macaque (60 min,
room temperature). After three washes with blocking buffer,
the membranes were incubated (30 min, room temperature)
with a 1:5,000 dilution of a horseradish peroxidase-conju-
gated sheep anti-human immunoglobulin G antibody (Amer-
sham) and then washed five times with blocking buffer and
one time with phosphate-buffered saline. The membranes
were then processed by using enhanced chemiluminescence
as instructed by the manufacturer (Amersham).
RNA analysis. All RNAs were prepared as previously
described (42). For Northern (RNA) blot analysis, total
RNAs were separated on 1% agarose-formaldehyde gels and
transferred to nylon membranes (Duralon U.V.; Stratagene).
To measure the proportion of spliced-TAR-containing viral
mRNAs from infected cells, duplicate blots were hybridized
with 32P-end-labeled oligonucleotide probes specific for ei-
ther unspliced or spliced TAR RNA as previously described
(43).
RNase protection assays were performed essentially as
described previously (36), with hybridizations at 55°C for 14
to 18 h. The RNA probes used in these assays were
synthesized with T7 RNA polymerase and electrophoreti-
cally purified. These probes were homologous to nucleotides
+104 through +307 of SIVmac and contained an additional
122 nucleotides of vector sequence at their 3' ends. RNase-
resistant fragments were resolved on 6% acrylamide-7 M
urea gels.
In vitro transcription and translation. To synthesize
capped RNAs for in vitro translation, plasmid templates
were linearized at the BamHI site located just after the CAT
protein coding region. To synthesize TAR RNAs lacking the
CAT coding region, the plasmids were linearized at the
HindIII site located at the TAR-CAT junction. The in vitro
transcription reaction mixtures contained 40 ,ug of template
DNA per ml, 40 mM Tris (pH 7.9), 6 mM MgCl2, 2 mM
spermidine, 10mM dithiothreitol, 0.01% Triton X-100, 2 mM
each ATP, CTP, and UTP, 0.2 mM GTP, 2 mM m7GpppG,
1 U of RNasin (Promega) per RI, and 1 U of T7 RNA
polymerase per ,ul. For the synthesis of 32P-labeled, capped
mRNAs, the reaction mixtures contained 0.5 mM each ATP
and CTP, 0.1 mM UTP, 0.05 mM GTP, 3.125 ,uM
[a-32P]UTP (100 ,uCi/40 p.l), and 0.5 mM m7GpppG. Reac-
tions were carried out at 37°C for 1 h. Template DNA was
removed by digestion with RQ-1 DNase (Promega). After
phenol-chloroform extraction and ethanol precipitation, the
RNAs were electrophoretically purified on 3.5% polyacryl-
amide-7 M urea gels. The TAR RNAs used in the preincuba-
tion experiments were further purified on 3.5% nondenatur-
ing polyacrylamide gels.
In vitro translations were performed by using rabbit retic-
ulocyte lysates (Bethesda Research Laboratories) and
[35S]methionine essentially according to the manufacturer's
protocols. The reaction mixtures contained final concentra-
tions of 90 mM K+ and 1.04 mM Mg2' and were supple-
mented with 1.33 U of RNasin per p.l. Prior to electropho-
resis, samples were digested with 20 p.g of RNase A per ml
(10 min, 37°C). The samples were analyzed on SDS-10%
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polyacrylamide gels. The gels were treated with Amplify
(Amersham) prior to autoradiography.
trans-inhibition assays were performed as described pre-
viously (9).
To analyze the ribosomal distribution of 32P-labeled
mRNAs, standard 30-,ul translation reaction mixtures con-
taining 100 ,uM unlabeled L-methionine were incubated at
30°C for 12 min and then diluted 10-fold into ice-cold buffer
A (25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid [HEPES, pH 7.3], 75 mM KCl, 2 mM magnesium
acetate, 50 ,ug of cycloheximide per ml) and fractionated on
gradients of 10 to 30% sucrose in buffer A. Centrifugation
was at 200,000 x g for 180 min at 4°C in an SW40 rotor.
RNA secondary structure analysis. The 5' ends of KGTAR
and KGATAR RNAs were dephosphorylated with calf intes-
tine alkaline phosphatase. The dephosphorylated 5' ends
were labeled with [_y-32P]ATP and polynucleotide kinase.
The end-labeled RNAs were electrophoretically purified.
Prior to nuclease digestion, the RNAs (104 cpm in the
appropriate reaction buffer) were heated to 70°C for 3 min
and then slowly cooled to room temperature. Digestions
with RNase T1 and nuclease Si under nondenaturing condi-
tions were done as described previously (41). Digestions
with RNase T1 under denaturing conditions to produce size
markers were done as instructed by the manufacturer (Phar-
macia). Partial alkaline hydrolysis to produce size markers
was done as described previously (41). All digestion mix-
tures contained yeast tRNA (3 ,ug) in order to maintain a
constant amount of RNA.
Digestion products were resolved on 6% acrylamide-7 M
urea gels. Autoradiography was at -80°C with an intensify-
ing screen.
RESULTS
The proportion of viral RNAs containing a spliced TAR
element decreases late in infection. Previously, we reported
that the 5' untranslated ends of all size classes of SIVmac
mRNAs can be modified by splicing (43). In chronically
infected cells, approximately 10% of viral mRNAs splice an
intron which extends from nucleotides +60 through +203
and which overlaps the predicted TAR structure (Fig. 1A).
We now examine the role ofTAR splicing in the life cycle of
SIVmac. As a first step, we examined whether the propor-
tion of viral mRNAs containing a spliced TAR element
changes throughout the course of infection. CEMx174 cells
were infected at a multiplicity of 0.01 infectious virion per
cell. Total RNAs were prepared at either 91 h or 15 days
after infection and examined by Northern blot analysis.
Duplicate blots were hybridized with oligonucleotide probes
specific (43) for either the spliced or unspliced form of TAR
(Fig. 2). Since the TAR intron splice acceptor site is located
within the U5 region of the LTR, only the 5' TAR element of
viral mRNAs can be spliced. Taking this into account, we
measured the level of TAR splicing at the different times
after infection by densitometry. There is proportionally
more spliced TAR early after infection than there is later. At
91 h after infection, approximately 60% of viral RNAs
contain a spliced TAR element; in contrast, at 15 days,
approximately 10% of viral RNAs contain a spliced TAR
element. Furthermore, since each size class of viral mRNA
(9.6, 4.5, and 2.0 kb) contains the same proportion of spliced
TAR, it appears that TAR splicing is independent of other
viral splicing events. The temporal change in the proportion
A
-506 +1 +185 +300 (+46 inaSlVmac5' sicesie)
U3 R U5 some
+60 +204
B
AC GGUCG CUA?%UCCAGCA A.u>C S S_____AUUGU %A\AAU nl
CU~~~~~~~~~~~~
FIG. 1. Position of the intron which overlaps SIVmac TAR. (A)
Diagram of the 5' end of the SIVmac genome, including the LTR.
Numbers refer to SIVmac nucleotide positions relative to the start
site of transcription (+ 1). The line at the top indicates the sequences
which form the TAR RNA secondary structure. The arrows shown
below indicate the position of the intron. Nucleotide position +466
is the site of the splice donor identified for all SIVmac subgenomic-
length mRNAs. (B) Predicted secondary structure of SIVmac TAR
RNA (1). Positions of the TAR intron 5' and 3' splice sites are
shown. Mutations that have been introduced at these sites are
indicated in the boxes. The provirus clone pBKSA1 contains the 3'
splice site mutations, while clone pBKSD12A1 contains both the 5'
and 3' splice site mutations. To maintain the TAR stem structure in
mutant pBKSD12A1, an additional mutation was introduced down-
stream of the TAR intron 5' splice site.
of spliced TAR-containing RNAs suggested that TAR splic-
ing may play a regulatory role in the SIVmac life cycle.
Requirement for TAR RNA splicing in the virus life cycle.
To determine whether TAR splicing is required for virus
replication, we constructed proviruses containing mutations
at the TAR intron splice sites. We first changed the dinucle-
otide AG at the TAR intron 3' splice site to the dinucleotide
TC (Fig. 1B). Similar changes in other eukaryotic genes
inactivate splicing (reviewed in references 13 and 28). This
mutation was predicted to affect only TAR intron splicing
since it does not lie within any other known viral coding or
regulatory region. This change was introduced into both the
5' and 3' LTRs of the biologically active, wild-type provirus
clone pBK.1, resulting in mutant pBKSA1. Because muta-
tion of a 3' splice site might activate cryptic sites, we also
constructed a provirus with mutations at both the 5' and 3'
splice sites. We therefore changed the sequence AG/GT at
the TAR intron 5' splice site of clone pBKSA1 to AC/CT (I
denotes the cleavage site) to generate the double mutant
pBKSD12A1.
All three virus clones, pBK.1, pBKSD12A1, and pBKSA1,
were transfected into CEMx174 cells. Cell-free superna-
tants, total RNAs, and total cell lysates were isolated at
various times after transfection.
RNase protection analysis demonstrated that the muta-
tions contained within pBKSA1 and pBKSD12A1 prevent
TAR splicing as predicted (Fig. 3A). Furthermore, since no
novel fragments were protected by RNA isolated from the
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FIG. 2. Northern blot analysis of RNAs isolated from CEMx174
cells at different times after SIVmac infection (Time P.I.). (A)
Duplicate blots were hybridized with oligonucleotide probes that are
specific for either unspliced or spliced TAR RNAs. (B) To control
for the amount of RNA in each lane, the blots were rehybridized
with a probe homologous to the 1-actin gene.
mutant virus-infected cells, these results also indicate that
the mutations contained with pBKSA1 and pBKSD12A1 did
not activate cryptic splice sites.
The steady-state level of virus produced at various times
after transfection (Fig. 3B) was measured by reverse tran-
scriptase assays. Both mutants displayed significantly lower
virus production at early times after transfection (1 to 20
days) but achieved a level of virus production comparable to
the wild-type level at later times (25 to 30 days). The
wild-type virus-infected culture required approximately 8
days to achieve one-half of maximal virus production, com-
pared with the approximately 20 days required for both
mutant viruses. The delayed growth of the mutants did not
reflect the selection of revertants, since this phenotype was
stable upon infection of fresh CEMx174 cells (Fig. 3C).
These experiments therefore demonstrated that TAR splic-
ing is required for efficient viral replication.
Northern blot analysis of RNAs prepared from the various
cultures at different times after transfection indicated that
the mutants accumulated low levels of viral mRNA early
after transfection but near-wild-type levels at later times
(Fig. 3D). Moreover, the mutant viruses expressed the 9.4-,
4.5-, and 2.0-kb classes of RNA in proportions similar to
those expressed by the wild-type virus and did not express
any novel size classes of RNA, indicating that the overall
patterns of viral RNA expression were not affected. The
diminished level of RNA accumulation observed for the
TAR-splicing mutants does not appear to be due to an
inhibition of Tat-mediated transcriptional activation, since
LTR-CAT reporter gene constructs containing these muta-
tions were fully activated by Tat in transient assays (data not
shown).
To determine whether the mutant viruses expressed al-
tered levels or patterns of protein, we analyzed total cell
extracts by Western blotting with serum that recognizes the
SU (gpl20), Gag precursor (p57), and CA (p28) viral proteins
(Fig. 3F). The mutants expressed low levels of these proteins
at early times after transfection but near-wild-type levels at
later times. Furthermore, mutant and wild-type viruses
expressed similar proportions of these proteins, indicating
that the overall patterns of viral protein expression were not
effected.
Spliced-TAR-containing mRNAs are translated more effi-
ciently in vitro than are unspliced-TAR-containing mRNAs.
Taken together, the results described above indicate that
splicing of the TAR intron is required for the efficient
replication of SIVmac in CEMx174 cells. Although we found
that the accumulation of both viral RNA and proteins as well
as the production of cell-free virus were delayed in the
mutants, we were not able to determine the level of gene
expression directly effected by TAR splicing. However,
because there was a general down-regulation of virus expres-
sion and because we found that the splice site mutations did
not effect Tat-mediated activation, we hypothesized that
TAR splicing might affect the translational efficiency of viral
mRNAs. To test this hypothesis, we synthesized capped
CAT mRNAs (Fig. 4) containing either an unspliced TAR
leader (TARCAT), a spliced TAR leader (lATARCAT), or no
viral leader (¢D-CAT) and examined their translational effi-
ciency in rabbit reticulocyte lysates (Fig. 5). These experi-
ments demonstrated that both forms of SIVmac TAR sub-
stantially inhibited the translation of CAT mRNAs. More
importantly, however, CAT mRNAs containing a spliced
TAR leader sequence were translated better than were
mRNAs containing an unspliced TAR leader (Fig. 5A). At
low levels of input RNA (0.12 to 0.36 pmol), CAT messages
containing a spliced TAR leader were translated up to
8.5-fold more efficiently than were CAT messages containing
an unspliced TAR leader (Fig. SB). This difference in trans-
lational efficiency became less pronounced when greater
amounts (0.72 to 2.4 pmol) of RNA were added to the
lysates. The decrease in translational efficiency may be due
to limiting amounts of translation factors, since a similar
decrease was found when increasing amounts of CAT mes-
sages lacking a TAR leader were added to the lysates (data
not shown).
To determine whether the difference in translational effi-
ciency observed between TARCAT and ATARCAT mRNAs
might be due to differences in the lengths of their leader
sequences (TARCAT [508 nucleotides] versus ATARCAT
[364 nucleotides]), we examined the translation of an addi-
tional CAT mRNA, AHCAT (Fig. SA). The AHCAT mRNA
leader sequence is 258 nucleotides long and includes those
bases required to form the unspliced TAR structure. Since
TARCAT and AHCAT mRNAs were translated with equal
efficiency, we conclude that leader length does not signifi-
cantly contribute to the difference in translational efficiency
observed between the TARCAT and ATARCAT mRNAs.
To determine whether the translational inhibition ob-
served for the different TAR structures might be due to a
contaminating inhibitory factor(s) present in the RNA prep-
arations, we examined the ability of these mRNAs to inhibit
the translation of globin mRNAs that were present in trans.
We found that all three forms of CAT mRNA (TARCAT,
ATARCAT, and 4)-CAT) inhibited globin translation approx-
imately twofold (data not shown). However, because all
three mRNAs inhibited globin mRNA translation to the
same extent, we conclude that the differences in transla-
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FIG. 3. Analysis of the effects of TAR splicing mutants on the replication of SIVmac. (A) RNase protection assay to determine whether
the TAR intron splice site mutations prevent splicing. CEMx174 cells were transfected with either a wild-type (W.T.) provirus clone (BK.1)
or with clones containing a mutation at either the TAR intron 3' splice site (pBKSA1) or both 5' and 3' splice sites (pBKSD12A1). Total RNAs
were prepared at various times after transfection and analyzed with antisense RNA probes homologous to a portion of the SIVmac LTR. The
probe used to analyze mRNAs expressed by BKSA1 and BKSD12A1 contained the same mutation at the 3' TAR intron splice site that is
found in the mutant proviruses. Positions of the probes, as well as the expected protected fragments, are shown at the bottom. DNA molecular
weight size standards (nucleotides) are shown at the right. The identities of the spliced and unspliced TAR fragments were confirmed by
comparison with fragments protected by in vitro-synthesized TAR RNAs (data not shown). The 140-nucleotide fragment was also protected
by in vitro-synthesized unspliced TAR RNA (not shown), indicating that it is most likely the result of the TAR region secondary structure.
The 82-nucleotide protected fragment corresponds to transcripts terminating within the 3' LTR. P.T., posttransfection; nuc., nucleotides. (B
and C) Reverse transcriptase activity. (B) Cell-free supernatants were prepared from the various cultures and analyzed for reverse
transcriptase activity. These values were normalized against the number of cells in each culture and plotted versus the number of days
posttransfection. (C) Cell-free supernatants prepared at day 32 after transfection were used to infect fresh CEMx174 cells (107 cpm/5 x 106 cells).
The level of cell-free reverse transcriptase activity in these cultures was measured at various times after infection and plotted as in panel B. (D
and E) Northern blot analysis. (D) Total RNAs prepared from the transfected cultures were hybridized with a probe homologous to the SIVmac
LTR. (E) To control for the amount of RNA in each lane, the blot was rehybridized with a probe homologous to the P-actin gene. P.T.,
posttransfection. (F) Western blot analysis. Total cell lysates prepared from the transfected cultures (the equivalent of 10i cells) were separated
on 10% acrylamide-SDS gels. Viral proteins were detected by incubation with serum from an SIVmac-infected rhesus macaque followed by
incubation with horseradish peroxidase-conjugated sheep anti-human immunoglobulin G and processed by using enhanced chemiluminescence.
Molecular size standards (kilodaltons) and the identities of viral proteins are shown at the right. P.T., posttransfection.
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FIG. 4. Structures of plasmids used as templates for in vitro
transcription. (A) Plasmids used for the in vitro transcription ofCAT
mRNAs containing different untranslated leader sequences. The
bacteriophage T7 promoter is indicated. R and U5 indicate different
regions of the SIVmac LTR; CAT, the coding region of the bacterial
CAT gene. The double-headed arrow indicates those nucleotides
which form the TAR structure. The BamHI sites used to linearize
the templates are indicated.
tional efficiency observed between the three CAT mRNAs
are not due to contaminating inhibitory factors.
We also measured the stability of the three CAT mRNAs
during the translation reaction. Since the three RNAs were
equally stable (data not shown), we conclude that differences
in RNA stability do not contribute to the observed differ-
ences in the levels of in vitro translation.
Translational inhibition is mediated through a cis-acting
mechanism. The difference in translational inhibition that we
observed between the unspliced and spliced forms of TAR-
containing mRNAs may be affected by either a cis- or
trans-acting mechanism. To determine whether the different
TAR structures affect translation in trans, we preincubated
rabbit reticulocyte lysates for 10 min with either unspliced
(8.3 ng/ml to 5 ,ug/ml) or spliced (5.7 ng/ml to 3.45 j±g/ml)
TAR RNAs that lack a protein coding region. Following the
preincubation, (F-CAT mRNAs were added and translation
was allowed to proceed for 1 h. We found that preincubation
with the different TAR RNAs had no effect on the translation
of ¢F-CAT mRNA (Table 1). However, when the lysates
were preincubated with poly(I) poly(C) (2 to 10 ng/ml),
which is known to activate the double-stranded RNA-depen-
dent protein kinase dsl, there was an approximately fivefold
inhibition of (¢-CAT translation (Table 1). These results
indicate that under the conditions used, SIVmac TAR RNAs
do not have a trans-inhibitory effect on translation.
We next addressed whether the two forms of TAR differ-
entially affected the ability of mRNAs to associate with
ribosomes. Capped, 32P-labeled TARCAT, ATARCAT, and
(¢-CAT mRNAs were translated in rabbit reticulocyte lysates
for 12 min at 30°C and then analyzed on 10 to 30% sucrose
gradients (Fig. 5C). These experiments demonstrated that
both forms of SIVmac TAR inhibited the association of
mRNAs with ribosomes. More importantly, however, they
demonstrated that ATARCAT mRNAs were associated with
ribosomes approximately twofold more efficiently than were
TARCAT mRNAs. These results therefore indicate that splic-
ing of the TAR structure relieves a cis-acting inhibition to the
association of mRNAs with ribosomes.
Secondary structures of the spliced and unspliced forms of
TAR. Computer predictions indicated that splicing of SIV-
mac TAR RNA results in a simpler structure. Since this
change might be related to the observed differences in
biological activity, we wanted to experimentally determine
the two TAR secondary structures. We therefore synthe-
sized 5' 32P-end-labeled spliced and unspliced TAR RNAs in
vitro and digested them under nondenaturing conditions with
limiting amounts of either RNase T1 or nuclease S1. The
resultant partial digestion products were then separated on 7
M urea-acrylamide gels (Fig. 6A). These experiments indi-
cated that the predicted RNA structures of the unspliced and
spliced forms of SIVmac TAR are substantially correct (Fig.
6B). The unspliced TAR RNA contains three T1-hypersen-
sitive regions which correspond to the positions of the three
predicted loops. Furthermore, nucleotides which are pre-
dicted to be adjacent to, or part of, a single-stranded bulge
are also sensitive to either T1 or S1 digestion (for example,
G25 and C48). In one instance (G57), S1 nuclease preferen-
tially digested a nucleotide that is predicted to be part of a
double-stranded region. This may reflect breathing of the
RNA duplex or be a consequence of the tertiary structure.
The spliced form of TAR contains a single T1-hypersensitive
region corresponding to a predicted loop. Furthermore, as
with unspliced TAR, nucleotides that are predicted to be
adjacent to or part of a single-stranded bulge are sensitive to
T1 or S1 digestion. However, in contrast to unspliced TAR,
the 5' end of spliced TAR is sensitive to nuclease digestion.
These results suggest that the 5' end of spliced TAR RNA is
either weakly base paired or unpaired whereas the 5' end of
unspliced TAR RNA is mostly or fully base paired.
DISCUSSION
The results presented in this report demonstrate that
splicing of the TAR element is required for the efficient
replication of SIVmac. Mutant viruses which cannot splice
TAR show an overall repression of virus expression at early
times after infection but near-wild-type levels at later times.
The ability of these splicing mutations to reduce the accu-
mulation of both viral RNA and protein as well as the
production of cell-free virions is most simply explained by a
decrease in the translational efficiency of viral mRNAs
containing an unspliced TAR leader sequence. We found
that in rabbit reticulocyte lysates, CAT mRNAs containing
an unspliced TAR leader sequence were translated up to
8.5-fold less efficiently than were similar RNAs containing a
spliced TAR leader sequence. Therefore, since all size
classes of SIVmac mRNA can splice the TAR intron, it is
expected that overall viral protein synthesis will be de-
pressed for those viruses containing the TAR-splicing muta-
tions. This decrease in protein synthesis should include a
decrease in the level of the transcriptional activator, Tat.
Since active transcription of the SIVmac LTR is dependent
on Tat (1, 42), inhibition of viral translation should also
result in a decrease in viral transcription.
Although the simplest explanation for the delayed growth
pattern seen for the TAR-splicing mutants is a change in
translational efficiencies, we cannot at this time rule out that
TAR splicing does not also subtly effect other levels of
expression such as Tat-mediated transcription, mRNA turn-
over, or RNA compartmentalization.
Two distinct models have been proposed to explain the
translational inhibition caused by HIV-1 TAR. The first
considers the accessibility of the 5' end of TAR-containing
mRNAs to binding by translation initiation factors (29, 38).
According to the scanning model for the translation of
eukaryotic mRNAs (reviewed in reference 21), one of the
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FIG. 5. In vitro translation of CAT mRNAs containing different
untranslated leader sequences. (A) In vitro-synthesized, capped CAT
mRNAs containing different leader sequences were translated in
rabbit reticulocyte lysates, and the products were separated on 10%
acrylamide-SDS gels. Details are given in Materials and Methods.
The lower panel is a longer exposure of the upper panel. (B) To
quantify the effects of the different TAR structures on translation, an
autoradiograph of the in vitro translation of increasing amounts of
mRNA was scanned with a laser densitometer. The relative amounts
of CAT protein translated per mole of RNA were plotted against the
amount of input RNA. (C) Polysome distribution ofmRNAs. Capped,
32P-labeled RNAs (0.29 pmol) were incubated for 12 min at 30°C in a
first steps in initiation is the binding of a 40S ribosome
subunit-translation initiation factor complex to the 5'
m7GpppN cap structure. Binding of this complex can be
prevented by RNA secondary structures which limit access
to the cap structure (19, 20, 30). Therefore, mRNAs which
have their 5' ends sequestered within the secondary struc-
ture of HIV-1 TAR are inefficiently translated. This model is
supported by the observation that wild-type HIV-1 TAR
RNAs exhibit low binding to the initiation factor eIF-4B
whereas TAR RNAs containing a mutation that reduces
secondary structure adjacent to the cap bind eIF-4B about
fivefold more efficiently (29). Moreover, second-site muta-
tions which restore the secondary structure also lower
eIF-4B binding back to near wild-type levels.
The differences in translational efficiency that we ob-
served for CAT mRNAs containing either spliced or un-
spliced SIVmac TAR leader sequences are consistent with
this type of model. We used single-strand-specific nucleases
to probe the secondary structures of both forms of TAR
RNA. The results obtained from these experiments agree
with computer predictions of the RNA secondary structures
and indicate that the 5' end of unspliced TAR, including
nucleotide position + 1, is base paired. In contrast, the 5' end
of spliced TAR is most likely either weakly paired or un-
paired. This model predicts that the cap structure of spliced
TAR is more accessible to binding by the 40S ribosome
subunit-initiation factor complex than is the cap structure of
unspliced TAR. Consistent with this model, we found that
mRNAs containing a spliced TAR leader are more efficiently
associated with ribosomes than are similar mRNAs contain-
ing an unspliced TAR leader. Whether the increased associ-
ation of spliced-TAR-containing mRNAs is the result of a cap
structure that is more accessible to 40S ribosome subunit-
initiation factor complex binding remains to be determined.
An alternative model that has been proposed to explain
the translational inhibition found for HIV-1 is that TAR
RNA activates the double-stranded RNA-dependent protein
kinase dsl (also called DAI or p68) (9, 38, 39). The activated
form of this kinase phosphorylates the a subunit of the
initiation factor eIF-2 (reviewed in references 23 and 32).
When it is phosphorylated, eIF-2 cannot be recycled and
translation is inhibited. This model is supported by the
observation that wild-type TAR RNAs have a trans-inhibi-
tory effect on the translation of other mRNAs whereas
mutant TAR RNAs with less secondary structure do not (9).
Furthermore, the ability of these mutant TAR RNAs to
inhibit translation in trans is restored when they contain
additional compensatory mutations which also restore their
secondary structure. More direct evidence that HIV-1 TAR
can activate dsl stems from experiments demonstrating that
wild-type TAR RNAs stimulate the in vitro phosphorylation
of both dsI and eIF-2at (9). A recent study has, however,
indicated that the activation of dsI described above may be
the result of contaminating double-stranded RNAs that were
generated during the in vitro synthesis of the TAR RNA (14).
rabbit reticulocyte translation reaction. The reaction mixtures were
fractionated through 10 to 30% sucrose gradients. Fractions were
collected from the top of the gradients, and the radioactivity in each
fraction was measured by liquid scintillation. Values were adjusted
to compensate for the specific activities of the RNAs. The position
of the 80S ribosome peak is indicated. Numbers at the top indicate
the percentage of the total added radioactivity associated with each
peak. A representative experiment is shown.
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TABLE 1. trans-inhibition of translation by different RNAsa
RNA added during Relative level of
preincubation ¢D-CAT translation
TAR
16.7 ng/ml (0.11 nM) .................................... 1.10
66.7 ng/ml (0.44 nM) .................................... 1.05
333 ng/ml (2.2 nM) ..................................... 1.06
1 p.g/ml (6.6 nM)..................................... 0.91
4 ,ug/ml (26.0 nM) ..................................... 0.96
10 ,ug/ml (66.0 nM)..................................... 1.16
ATAR
11.3 ng/ml (0.11 nM) .................................... 0.97
46 ng/ml (0.44 nM) ..................................... 0.80
230 ng/ml (2.2 nM) ..................................... 1.06
690 ng/ml (6.6 nM) ..................................... 1.03
2.8 p.g/ml (26.0 nM)..................................... 1.17
6.9 jig/ml (66.0 nM)..................................... 1.18
Poly(I) poly(C)
4 ng/ml ............ ......................... 0.19
20 ng/ml ............. ........................ 0.22
a Rabbit reticulocyte lysates were preincubated (10 min, 30°C) with the
indicated amount of RNA. 4¢-CAT mRNA (2 pg/ml) was then added, and
translation was started and allowed to proceed (1 h, 30'C). The translation
products were resolved on SDS-polyacrylamide gels. Levels of 4)-CAT
mRNA translation were quantified with a Molecular Dynamics Phosphorlm-
ager. Ratios of ¢)-CAT translation in preincubated lysates compared with that
in normal lysates are shown.
In fact, this study further suggests that high levels of purified
TAR RNA inhibit rather than stimulate the activation of dsL.
Our experiments indicate that neither the spliced nor
unspliced form of SIVmac TAR is capable of inducing a
trans-inhibitory effect on translation. Under identical exper-
imental conditions, we were however, able to induce a
down-regulation of translation by using the dsl-activating
double-stranded RNA poly(I) poly(C). Therefore, the pre-
dominant effect of the SIVmac TAR leader on CAT mRNA
translation appears to be independent of the activation of dsI
or of any other trans-acting mechanism.
TAR RNA splicing appears to be specific to the SIVsmm
group of primate lentiviruses. Although we have examined
TAR splicing only in SIVmac, the splice donor and acceptor
sites of the TAR intron are conserved in other viruses from
this group, including SIVs isolated from sooty mangabeys
(SIVsmm) and pig-tailed macaques (SIVmne) and in HIV-2
(26). In contrast, these sites are not conserved in viruses
from the HIV-1, SIVagm, or SIVmnd group (26). Why TAR
RNA splicing is apparently specific to the SIVsmm group of
viruses is not understood.
Taken together, the results presented in this report suggest
a model in which TAR splicing plays a pivotal role in the
SIVmac life cycle. Spliced TAR-containing mRNAs are
more efficient templates for translation than are mRNAs
containing an unspliced TAR. We postulate that this prop-
erty is due to their simpler and less stable secondary
structure. At early times after infection, a high proportion of
viral mRNAs contain a spliced TAR element. These mRNAs
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FIG. 6. Partial digestions of either unspliced or spliced TAR RNAs. (A) 5' 32P-end labeled unspliced TAR RNAs were digested with
limiting amounts of either RNase T1 or nuclease S1 and electrophoresed on 6% acrylamide-7 M urea gels. Lanes: OH-, partial alkaline
hydrolysis; T1D; RNase T1 digestion under denaturing conditions (3.5 M urea) with either 0.07 or 0.33 U of RNA per pLg; T1, RNase T1
digestion under nondenaturing conditions with either 0.33 or 1.67 U of RNA per p,g; Sl, nuclease S1 digestion under nondenaturing conditions
with either 0.04 or 0.2 U of RNA per p,g. (B) 5' 32P-end labeled spliced TAR RNAs were digested with limiting amounts of either RNase T1
or nuclease S1 and electrophoresed on 6% acrylamide-7 M urea gels. Lanes: OH-, partial alkaline hydrolysis; T1D; RNase T1 digestion under
denaturing conditions (3.5 M urea) with either 0.07 or 0.33 U of RNA per pg; T1, RNase T1 digestion under nondenaturing conditions with
either 0.33 or 1.67 U of RNA per p,g; Sl, nuclease S1 digestion under nondenaturing conditions with either 0.02 or 0.2 U of RNA per pg. (C)
Predicted secondary structures of spliced and unspliced TAR RNAs and the positions of nuclease sensitivity. Computer-generated secondary
structure predictions were made by using the FOLD program (17). The structure of unspliced TAR is the same as previously described (1).
The sites of nuclease digestion are indicated.
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would be efficiently translated and thereby increase the
production of viral proteins. Late in infection, the proportion
of mRNAs containing a spliced TAR decreases, thereby
decreasing the production of viral proteins. Concomitant
with the decrease in TAR splicing is an increase in the level
of full-length genomic RNAs which are required for virion
production. We hypothesize that the level of TAR splicing
may provide a balance for the optimum expression of both
viral proteins and genomic RNA and therefore ultimately
control the production of infectious virions.
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